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ABSTRACT
Ovarian cancer is the 5th leading cause of cancer death among women in the 
United States. The mevalonate pathway is thought to be a potential oncogenic pathway 
in the pathogenesis of ovarian cancer. Simvastatin, a 3-hydroxy-3-methyl-glutaryl-CoA  
reductase (HMGCR) inhibitor, is a widely used drug for inhibiting the synthesis of 
cholesterol and may also have anti-tumorigenic activity. Our goal was to evaluate the 
effects of simvastatin on ovarian cancer cell lines, primary cultures of ovarian cancer 
cells and in an orthotopic ovarian cancer mouse model. Simvastatin significantly 
inhibited cellular proliferation, induced cell cycle G1 arrest and apoptosis, and caused 
cellular stress via reduction in the enzymatic activity of HMGCR and inhibition of the 
MAPK and mTOR pathways in ovarian cancer cells. Furthermore, simvastatin induced 
DNA damage and reduced cell adhesion and invasion. Simvastatin also exerted  
anti-proliferative effects on primary cell cultures of ovarian cancer. Treatment with 
simvastatin in an orthotopic mouse model reduced ovarian tumor growth, coincident 
with decreased Ki-67, HMGCR, phosphorylated-Akt and phosphorylated-p42/44 
protein expression. Our findings demonstrate that simvastatin may have therapeutic 
benefit for ovarian cancer treatment and be worthy of further exploration in clinical 
trials.
INTRODUCTION
Ovarian cancer is the 5th leading cause of cancer 
death among women with an estimated 21,290 new 
cases diagnosed in the United States in 2015 and 14,180 
deaths [1] . The majority of these cancers are found in 
later stages. Initial treatment typically includes a surgical 
staging or a debulking procedure followed by adjuvant 
chemotherapy [2]. Overall survival for advanced ovarian 
cancer is poor, with less than 40% of patients surviving at 
5 years [2, 3]. Thus, there is a great need to develop more 
effective treatments for this deadly disease.
A growing body of literature supports obesity as 
a significant risk factor for the development of ovarian 
cancer [4–7]. In addition, obesity has been linked to 
worse outcomes and higher mortality from this disease 
[4, 7, 8]. The metabolic mechanisms for these phenomena 
are not fully understood. It is thought that obesity leads 
to elevated insulin signaling, inflammation, an increased 
availability of lipids, and changes in adipokine signaling 
that results in the conversion of normal epithelial cells to 
invasive tumor cells. Our recent results showed that the 
metabolic effects of obesity have been shown to promote 
ovarian cancer pathogenesis and aggressiveness in a 
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genetically engineered mouse model of serous ovarian 
cancer [5].
Simvastatin belongs to the statin class of drugs that 
are widely used in the treatment of hypercholesterolemia. 
It is an effective and well-tolerated drug with few side 
effects. Statins inhibit 3-hydroxy-3-methyl-glutaryl 
coenzyme A reductase (HMGCR), which is an enzyme that 
is required for the synthesis of mevalonate [3]. HMGCR 
is essential for the cellular synthesis of cholesterol and 
a variety of non-steroid isoprenoid derivatives involved 
in cell proliferation, differentiation and survival. In vitro 
and in vivo studies suggest that simvastatin inhibits 
cancer cell growth by inducing apoptosis and inhibiting 
cell cycle progression through a variety of cell signaling 
pathways [9–13]. Pre-clinical studies highlight the ability 
of statins to decrease cancer cell proliferation, invasion 
and metastasis by inhibiting the synthesis of cholesterol, 
required for cancer growth [14–16]. Phase II clinical 
trials have demonstrated that some patients may benefit 
from simvastatin combined with other chemotherapeutic 
agents [17].
Observational studies have shown a meaningful 
reduction in ovarian cancer risk with long-term use of 
statins [18, 19]. In a recent meta-analysis of the effect 
of statins in gynecologic cancers, the use of statins 
was associated with a significant 21% risk reduction 
(RR = 0.79; 95% CI, 0.64–0.98) in the incidence of 
ovarian cancer [20]. This risk reduction persisted with 
long term statin use >5 years (RR = 0.48; 95% CI, 
0.28–0.80) [20]. Despite these findings, there have been 
limited in vitro studies and no in vivo studies on the 
effects of simvastatin on ovarian cancer tumor growth. 
Thus, we sought to investigate the effect of simvastatin 
on cell proliferation, apoptosis, cellular stress, adhesion 
and invasion in ovarian cancer cells and in an orthotropic 
mouse model of ovarian cancer. Our results indicate that 
simvastatin demonstrates promise as a targeted agent for 
ovarian cancer.
RESULTS
Simvastatin inhibited cell growth and decreases 
HMGCR activity
The effect of simvastatin on cell proliferation was 
examined in the ovarian cancer cell lines, Hey and SKOV3. 
The cells were exposed to varying doses of simvastatin 
for 72 h. As shown in Fig. 1A, simvastatin effectively 
inhibited cell proliferation in a dose-dependent manner in 
both ovarian cancer cells. The mean IC50 value for each 
of these cell lines was approximately 10 uM and 8 uM 
for Hey and SKOV3 cells, respectively. In order to ensure 
that simvastatin had an inhibitory effect on its molecular 
target, we examined HMGCR protein expression and 
activity in both cell lines after exposure to varying doses 
of simvastatin (1, 10 and 25 uM) for 24 h. A significant 
decrease in protein expression and activity of HMGCR 
was seen in the Hey and SKOV3 cells (Fig. 1B–1C), 
co-incident with inhibition of proliferation.
Simvastatin induced cell cycle arrest in G0/G1 
and apoptosis
To evaluate the underlying mechanism of growth 
inhibition by simvastatin, the cell cycle profile was 
analyzed after treating the Hey and SKOV3 cells with 
varying doses (1–25 uM) of simvastatin for 24 h. 
Simvastatin treatment resulted in G0/G1 cell cycle arrest 
and reduced S phase in a dose-dependent manner in 
the cells (Fig. 2A and 2B). To further confirm whether 
the growth inhibition of ovarian cancer cells was 
related to apoptosis, we evaluated the apoptotic effect 
of simvastatin on Hey and SKOV3 cells by Annexin-V 
FITC stain analysis, which detects the phospholipid 
phosphatidylserine (PS) translocation from the inner 
(cytoplasmic) leaflet of the cell membrane to the external 
surface in very early apoptotic cells. As shown in Fig. 3A  
and 3B, after treatment of the cells with simvastatin 
at the indicated concentrations for 24 h, the percentage 
of early apoptotic cells increased in a dose-dependent 
manner in both cell lines. We next determined whether 
the mitochondrial apoptosis pathway, which leads to 
caspase activation and induces cell death, was involved 
in simvastatin-induced apoptosis in ovarian cancer cells. 
We treated both cells with the indicated concentration 
of simvastatin for 10 hours, and cleaved caspase 3 and 
cleaved caspase 9 proteins were determined by Western 
blotting using antibodies that specifically detect the cleave 
forms of the caspases. We observed a dose-dependent 
increase in expression of cleaved caspase proteins in both 
cell lines in response to simvastatin (Fig. 3C and 3D). In 
addition, we found simvastatin reduced BCL-2 protein 
expression in a dose dependent manner after treatment 
with simvastatin for 24 hours in Hey and SKVO3 cells 
(Fig. 3C and 3D). These result suggest that inducing 
mitochondrial apoptosis and cell cycle G1 arrest may 
be major mechanisms to inhibit cell proliferation in 
simvastatin treated ovarian cancer cells.
Simvastatin increased levels of intracellular ROS 
and resulted in DNA damage
Reactive oxygen species (ROS) have been 
implicated in the cellular response to stress and are 
involved in mediation of apoptosis via mitochondrial 
DNA damage [20]. To investigate the involvement 
of oxidative stress in the anti-proliferative effect of 
simvastatin, intracellular ROS levels were examined 
by using the ROS fluorescence indicator DCFH-
DA [17]. As seen in Fig. 4A and 4B, treatment with 
simvastatin (1–25 uM) for 18 h significantly increased 
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cellular ROS production in a dose-dependent manner 
in the Hey and SKOV3 cells. We next examined the 
changes of markers for endoplasmic reticulum (ER) 
stress after 24 h treatment of simvastatin in both cell 
lines. Western blotting showed simvastatin induced 
PERK and Bip protein expression in a dose dependent 
manner, which is further evidence of ER stress induction 
by simvastatin (Fig. 4C). Given that the production of 
peroxides and free radicals induced in oxidative stress 
can damage several cell components including nuclear 
Figure 2: Simvastatin induced cell cycle G1 arrest in ovarian cancer cells. The Hey A. and SKOV3 B. cell lines were treated 
with the indicated doses of simvastatin (1–25 uM) for 24 h. Cell cycle analysis was performed by Cellometer. Simvastatin markedly 
induced cell cycle G1 arrest in both cell lines in a dose dependent manner. Each experiment was performed three times. C in graphs refers 
to control. (*p < 0.05, **p < 0.01).
Figure 1: Simvastatin inhibited the growth of ovarian cancer cells and HMGCR activity. Hey and SKOV3 cells were 
cultured for 24 h and then treated with varying concentrations of simvastatin in 96 well plates for 72 h. Cell proliferation was assessed by 
MTT assay A. The effect of simvastatin on its target, HMGCR, was examined by Western blot analysis. Simvastatin treatment resulted in a 
dose-dependent decrease in expression of HMGCR protein in both cell lines B. HMGCR activity in ovarian cancer cells was measured via 
HMGCR Assay. Treatment with simvastatin for 24 h resulted in a dose-dependent decrease in HMGCR activity in both the Hey and SKOV3 
cell lines C. Each experiment was performed three times. C in graphs refers to control. (*p < 0.05, **p < 0.01).
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and mitochondrial DNA, we evaluated DNA damage by 
qPCR and found that simvastatin induced DNA damage 
in a dose-dependent manner in both the Hey and SKOV3 
(Fig. 4D and 4E) cells after 24 h of treatment. These 
results indicate that an increase in ROS and DNA damage 
might also be involved in the anti-tumorigenic effects of 
simvastatin in ovarian cancer cells.
Simvastatin inhibited cell adhesion and invasion
Adhesion and invasion are crucial to the evolution 
of metastatic disease. In order to determine the effect 
of simvastatin on invasive ability of ovarian cancer 
cells, in vitro laminin adhesion assay and transwell 
invasion system were employed. Incubation of the 
Hey and SKOV3 cells with simvastatin (1, 10 and 
25 uM) for 2 h showed significant inhibition of cell 
adhesion (Fig. 5A and 5B). Simvastatin significantly 
blocked ovarian cancer cell invasion after 24 h of 
treatment as determined by transwell invasion assay 
(Fig. 5C and 5D). Inhibition of cell adhesion and 
invasion was dose-dependent in the both cells. Since 
vascular endothelial growth factor (VEGF) is a key 
mediator of angiogenesis and invasion in cancer, 
we next sought to determine the direct effects of 
simvastatin on production of VEGF in both cell lines. 
Simvastatin significantly reduced the levels of VEGF 
in culture media and cell lysates after 36 hours of 
treatment (Fig. 5E and 5F). These results suggest 
that simvastatin may function to inhibit adhesion and 
invasion in ovarian cancer cells as well as inducing 
apoptosis, cell cycle arrest, cellular stress and reducing 
angiogenesis.
Effect of simvastatin on the AKT/mTOR and 
MAPK pathways
It is well known that activation of the extracellular 
signal regulated kinase (ERK)/mitogen-activated protein 
kinase (MAPK) and AKT/mammalian target of rapamycin 
Figure 3: Simvastatin increased apoptosis in ovarian cancer cells. The Hey A. and SKOV3 B. cell lines were cultured for 
24 h and then treated with simvastatin at different doses for 24 h. Apoptosis was examined by Annexin V assay in Cellometer. Caspase-3, 
Caspase-9 and BCL-2 were determined by Western immunoblotting after exposure to simvastatin for 10 h or 24 h C and D. Each experiment 
was performed three times. C in graphs refers to control. (*p < 0.05, **p < 0.01).
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(AKT/mTOR) pathways play a crucial role in the control 
of cell growth and survival in ovarian cancer and inhibition 
of these pathways leads to the inhibition of ovarian 
cancer growth [21, 22]. To investigate the mechanisms 
underlying the inhibition of cell growth by simvastatin, we 
characterized the effect of simvastatin on these signaling 
pathways. Simvastatin reduced phosphorylation of p42/44 
(ERK1/2) in a dose-dependent manner in both the ovarian 
cancer cell lines, within 24 h of exposure (Fig. 6). We then 
evaluated the effect of simvastatin on the AKT/mTOR/
S6 pathway. Western blotting showed that simvastatin 
decreased phosphorylation of AKT and S6 in both cell 
lines in a dose dependent manner after 24 h treatment (Fig. 
6). These data suggest that simvastatin may exert its anti-
tumor activity via inhibition of MAPK and AKT/mTOR/
S6 pathways.
Simvastatin decreased tumor growth in an 
orthotopic mouse model of ovarian cancer
To validate the anti-tumorigenic potential of 
simvastatin in vivo, we utilized an orthotopic serous 
ovarian cancer mouse model by injecting M909 cells 
into the ovary bursa of female mice [23]. The mice 
were treated with simvastatin (intraperitoneal injection, 
3 mg/kg/day) or placebo (saline) for 4 weeks after 
twelve days of injection with M909 cells. Tumor growth 
during the treatment was monitored by palpation twice 
a week. When tumors reached a certain size (more than 
0.4–0.5 cm), we measured the tumor size by caliper. 
During the treatment, the mice showed tolerance to 
simvastatin injections and maintained normal activities. 
Regular twice-weekly measurements yielded no 
Figure 4: Simvastatin caused cellular stress and DNA damage in ovarian cancer cells. The Hey A. and SKOV3 B. cell 
lines were treated with simvastatin at different concentrations for 18 h and reactive oxygen species (ROS) level was determined using 
DCFH-DA dye on a plate reader. PERK and Bip were determined by Western immunoblotting after exposure to simvastatin for 24 h 
C. DNA damage in the Hey D. and SKOV3 E. cell lines was analyzed by QPCR assay after treatment with simvastatin for 24 h. Each 
experiment was performed three times. (*p < 0.05, **p < 0.01). C in graphs refers to control.
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changes in blood glucose or weight (data not shown). 
After 4 weeks of treatment, the mice were euthanized, 
and the ovarian tumors were removed, photographed, 
and weighed. A substantial reduction in tumor growth, 
tumor weight was found in the simvastatin group in 
comparison with the placebo group (Fig. 7A and 7B). 
We also found that simvastatin significantly reduced 
cholesterol concentration in mouse serum (Fig. 7C), 
indicating that mevalonate pathway is able to impact 
the inhibition of tumor growth induced by simvastatin 
Figure 5: Simvastatin reduced on adhesion and invasion in ovarian cancer cells. The Hey A, C. and SKOV3 B, D. cell lines 
were cultured for 24 h and then treated as indicated with simvastatin in a laminin coated 96 well plate for 2 h to assess adhesion or a BME 
coated 96 transwell plate for 24 h to assess invasion, respectively. The data represents relative inhibition in each cell line. VEGF was 
measured by ELISA assay in culture media E. and cell lysates F. after a 36 h exposure to simvastatin. Each experiment was performed three 
times. (*p < 0.05, **p < 0.01). C in graphs refers to control.
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in vivo. Furthermore, simvastatin was shown to reduce 
VEGF production in mouse serum and tumor tissues by 
ELISA assays (Fig. 7D).
To further confirm the anti-tumorigenic activity 
and mechanism of simvastatin in vivo, the expression 
of Ki-67 (marker of cell proliferation), cleaved 
caspase 3 (marker of apoptosis), phosphorylated-AKT, 
phosphorylated-p42/44 and HMGCR was evaluated 
by immunohistochemistry. Consistent with our results 
in vitro, the expression of phosphorylated-AKT, 
phosphorylated-p42/44 and HMGCR was reduced in 
the mice treated with simvastatin but not in the placebo-
treated mice. Ki-67 was significantly reduced following 
simvastatin treatment compared to the controls, whereas 
simvastatin increased the levels of cleaved caspase 3 in 
the treated mice (Fig. 7E). These results confirm that 
simvastatin inhibits ovarian tumor growth via activation 
or inhibition of critical signaling pathways involved in 
proliferation and metabolism.
Simvastatin inhibited proliferation of ovarian 
cancer cells derived from patients
To expand on our work in established cell 
lines and ovarian cancer mouse model, we further 
investigated the effects of simvastatin on cell growth 
in primary cultures of ovarian cancer cells using the 
MTT assay. Our results demonstrated that the majority 
of the primary cultures responded to simvastatin, with 
5/7 cases achieving an IC50 (range: 3 to 23 uM) after 
72 h of treatment with simvastatin (Fig. 8A and 8B). 
To further investigate if HMGCR protein expression 
was associated with sensitivity to simvastatin, we 
detected the HMGCR protein by Western blot in all of 
the primary cultures of ovarian cancer cells (Fig. 8C 
and 8D). The results revealed no correlation between 
level of HMGCR expression and response to treatment 
with simvastatin in our primary cultures of ovarian 
cancer cells.
Figure 6: Simvastatin inhibited MAPK and AKT/mTOR pathways in ovarian cancer cells. Hey and SKOV3 cells were 
treated with simvastatin at different doses for 24 h. Phosphorylated-p42/44, phosphorylated-AKT and phosphorylated-S6 were assessed by 
Western blotting. Simvastatin inhibited the activity of MAPK and AKT/mTOR pathways in Hey and SKOV3 cells. Each experiment was 
performed two times. (*p < 0.05, **p < 0.01).
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DISCUSSION
In this study, we investigated the anti-neoplastic 
activity of simvastatin in human ovarian cancer cell lines, 
primary cultures of ovarian cancer cells and an orthotopic 
mouse model of ovarian cancer. Simvastatin was found to 
inhibit cellular proliferation, suppress HMGCR enzymatic 
activity, cause mitochondrial DNA damage, cell cycle 
arrest, induce apoptosis and cellular stress, and block 
cellular adhesion and invasion. Moreover, the growth 
inhibition induced by simvastatin was accompanied by 
inhibition of the MAPK and AKT/mTOR/S6 pathways. 
Treatment with simvastatin reduced ovarian tumor weight 
and volume in mice, which was coincident with a decrease 
in expression of Ki67, p-pAKT, p-p42/44 and HMGCR, 
and an increase in cleaved caspase 3. These observations 
are comparable to recent studies in breast, liver, melanoma 
and lung cancer, showing promising anti-tumorigenic 
effects of statins on the growth of cancer in vitro and 
in vivo [24–28].
Adhesion and invasion are early steps involved in 
the metastatic process for ovarian cancer, which has a 
complex molecular basis that involves adhesion molecules, 
cell surface receptors, oncogenes, chloride channels, fatty 
acid synthase, and focal adhesion kinase [29–32]. Several 
studies have reported that simvastatin inhibits adhesion and 
invasion in leukemias, hepatocellular cancer, melanoma 
and endometrial cancer through multiple cell signaling 
pathways such as the ROCK, MAPK and mTOR pathways 
[21, 25, 33–35]. Simvastatin has been found to reduce 
ovarian cancer cell adhesion to peritoneal mesothelial 
cells through decreased expression of VCAM-1 and β1 
integrin in vitro [36], suggesting that simvastatin may 
provide a novel therapeutic approach to the prevention of 
Figure 7: Simvastatin reduced tumor growth of orthotropic xenografts of serous ovarian cancer. M909 cells were injected 
into left side of the ovarian bursa of 6–8 week old mice. When the tumors reached ~50 mm3 (approximately 12 days after injection), the 
mice were treated with placebo or 3 mg/kg simvastatin once a day for 4 weeks. Tumor volume A. and weight B. were recorded during or 
after 4 weeks treatment. Simvastatin reduced serum cholesterol in the mice C. VEGF was measured by ELISA assay in mouse serum and 
tumor tissues D. The changes of Ki-67, cleaved caspase 3, HMGCR, phosphorylated-AKT and phosphorylated-p42/44 were assessed by 
immunohistochemistry in ovarian tumor tissues E. (*p < 0.05. **p < 0.01).
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peritoneal carcinomatosis. Overexpression of VEGF in 
primary tumor and serum has been associated with poor 
progression-free survival (PFS) and overall survival for 
patients with ovarian cancer [37]. Simvastatin treatment 
has been found to decrease serum VEGF levels in diabetic 
patients [38] and to reduce intra-tumoral VEGF in mice 
[39]. Our data finds that simvastatin inhibited adhesion 
and invasion in two ovarian cancer cell lines and reduced 
VEGF production in their culture media and cell lysates. 
In addition, treatment with simvastatin in a mouse model 
of ovarian cancer also decreased VEGF levels in serum 
and tumor tissues.
To date, there are few studies that have looked at 
statin’s anti-proliferative effects in gynecologic cancer 
cells [40]. One study analyzed the effects of lipophilic 
(simvastatin and lovastatin) versus hydrophobic 
(pravastatin) statins on cell proliferation in gynecologic 
cancer cell lines, primary cultures of endometrial cancer 
and normal tissues, and found that lipohillic but not 
hydrophilic statins induced cell death in a dose and time 
dependent manner in endometrial, ovarian and cervical 
cancer cells, whereas little or no toxicity was observed 
in normal cells [40]. Another study demonstrated that 
all statins except pravastatin resulted in cell growth 
arrest in either monolayer cultures or spheroids cultures 
through activation of the autophagy pathway in seven 
different ovarian cancer cell lines [3]. In order to clarify 
the molecular mechanism of simvastatin-induced growth 
arrest, we comprehensively investigated the effect of 
simvastatin on the cell cycle, apoptosis and cellular stress. 
Inhibition of growth induced by simvastatin led to G1 
cell cycle arrest and an increase in Annexin V expression 
in our ovarian cancer cells, which was accompanied 
by increased intracellular mitochondrial apoptosis, 
mitochondrial DNA damage and cellular ROS. Similar 
effects were observed in our orthotopic mouse model 
of ovarian cancer, which demonstrated that simvastatin 
blocked tumor growth via inhibition of the MAPK and 
mTOR/S6 pathways and activation of the mitochondrial 
apoptosis pathway. Increased ROS levels occurred within 
24 h after simvastatin treatment, suggesting that redox 
imbalance is an early event induced by simvastatin in 
ovarian cancer cells. In fact, higher ROS production 
induced by simvastatin directly related to increased DNA 
damage, diminished DNA synthesis and caused cell cycle 
arrest in breast and liver cancer cells [41, 42].
Statins are known to reduce cell proliferation via 
down-regulation of critical signaling pathways in a few 
human cancers, including AKT/mTOR, MAPK, JAK2/
STAT3, Ras, NF-κB, JUNK and RhoA/ROCK pathways 
[9, 10, 43, 44]. In our previous study in simvastatin 
on endometrial cancer, we found that treatment with 
Figure 8: Simvastatin decreased cell proliferation in primary cultures of ovarian cancer cells. Cell proliferation was 
assayed by MTT assay in seven primary cultures of ovarian cancer cells after 72 h treatment with simvastatin A. The IC50 value for primary 
cultures is shown in B. HMGCR protein expression was detected by western blotting in the seven untreated primary cultures of ovarian 
cancer cells C, D. HMGCR expression did not predict sensitivity to simvastatin in ovarian cancer cells.
Oncotarget955www.impactjournals.com/oncotarget
simvastatin resulted in inhibition of the MAPK pathway 
and exhibited differential effects on the AKT/mTOR 
pathway in the ECC-1 and Ishikawa cells [35]. Similar 
results have been obtained in renal cancer cells and 
human myoblasts [44, 45]. The current study shows 
that simvastatin inhibited the protein expression of 
phosphorylated p42/44, AKT and S6 in in ovarian cancer 
cell lines and orthotropic xenografts of serous ovarian 
cancer, suggesting simvastatin reduced the activity MAPK 
and AKT/mTOR pathways in ovarian cancer. These results 
are consistent with previously published data, which 
confirmed that the MAPK and AKT/mTOR pathways 
regulated growth inhibition induced by simvastatin in vitro 
and in vivo.
We acknowledge that the doses of simvastatin used 
in our in vitro study (IC 50 value, 10 uM for Hey and 
8 uM for SKOV3, 3–23 uM for primary culture cells) 
are supra-therapeutic compared to the doses used in 
hypercholesterolemia patients. However, the range of 
doses are very similar to those used in other in vitro 
studies of simvastatin in cancer cells (1–30 uM) [31–34]. 
The maximum recommended clinical simvastatin dose is 
80 mg/day and the maximum tolerated dose of 
simvastatin is 15 mg/kg/day [46]. The therapeutic 
dose of simvastatin, 1 mg/kg/day, correlates to a 
serum level of 0.1 uM [36]. Our in vivo study found 
that simvastatin significantly inhibited the growth of 
orthotropic xenografts of ovarian cancer at a dose of 
3 mg/kg/day without any notable side effects, which is 
close to therapeutic concentrations clinically. This is a 
lower dose when compared to previously studied mouse 
models using 5 mg/kg/day [44].
Many epidemiological studies have shown a 
correlation between statins use and a relative reduction 
in the risk of endometrial, colorectal, gastric, and 
hepatocellular cancer [18, 47–51]. Currently, statins 
are being studied clinically for use in the prevention 
and treatment of cancer and as an adjuvant therapy in 
combination with chemotherapeutic agents. Two colorectal 
cancer studies reported a 17–51% reduction in colorectal 
cancer risk with simvastatin [50, 51]. Improved overall 
survival was seen in patients who used statins one year 
prior to the diagnosis of endometrial and ovarian cancers 
[18]. Reduced rates of advanced disease have been found 
among prostate cancer patients taking statins at the time 
of prostatectomy [52]. A clinical trial study comparing 
advanced liver cancer patients taking pravastatin versus a 
placebo showed increased survival amongst those patients 
who had been given the statin [53]. Breast cancer patients 
who were given atorvastatin two weeks prior to surgery 
showed anti-proliferative effects, with a decrease in Ki-67 
staining in those tumors that were HMGCR positive [54]. 
Although statins used as a single agent have shown some 
promise, statins may also be useful in combination with 
other cytotoxic agents. A phase II study using simvastatin 
plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) 
as first-line chemotherapy in metastatic colorectal cancer 
showed that time to progression was prolonged, and no 
additional adverse effects were seen with the addition of 
simvastatin [17]. Thus, given promising epidemiological 
and pre-clinical data, statins may be useful in the 
treatment and possibly prevention of many cancers, 
including ovarian cancer. Given that obese patients with 
ovarian cancer often suffer from co-morbidities such 
as hypercholesterolemia and diabetes, statins may be a 
particularly innovative treatment and prevention strategy 
in this high risk patient population.
MATERIALS AND METHODS
Cell culture and reagents
Hey and SKOV3 ovarian cancer cell lines were used 
in these experiments. Hey cells were maintained in RPMI 
1640 with 5% fetal bovine serum. SKOV3 cells were grown 
in DMEM/F12 with 10% fetal bovine serum. Simvastatin, 
MTT (3-(,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) and RNase A were purchased from Sigma 
(St. Louis, MO). The anti-phosphorylated-AKT, anti-pan-
AKT, anti-phosphorylated-p42/44, anti-pan-p42/44, anti-
phosphorylated-S6, anti-pan-S6, anti-cleaved caspase 3 and 
anti-BCL-2 antibodies were purchased from Cell Signaling 
(Beverly, MA). The anti-HMGCR antibody was from 
Santa Cruz (Dallas, Texas). Enhanced chemiluminescence 
Western blotting detection reagents were purchased from 
Amersham (Arlington Heights, IL). All other chemicals 
were purchased from Sigma.
Cell proliferation assays
The Hey and SKOV3 cells were plated and grown 
in 96-well plates at a concentration of 4000 cells/well for 
24 h. Cells were subsequently treated with varying doses 
of simvastatin for 72 h. MTT (5 mg/ml) was added to the 
96-well plates at 5 μl/well, followed by an additional hour 
of incubation. The MTT reaction was terminated through 
the addition of 100 μl of DMSO. The results were read by 
measuring absorption at 570 nm with a Microplate Reader 
(Tecan, Morrisville, NC). The effect of simvastatin was 
calculated as a percentage of control cell growth obtained 
from DMSO treated cells grown in the same 96-well 
plates. Each experiment was performed in triplicate to 
assess for consistency of results.
Apoptosis assay
Simvastatin induced apoptosis was detected with the 
Annexin V FITC kit (Biolegend, San Diego, CA) on the 
Cellometer (Nexelom, Lawrence, MA). Briefly, 2 × 105 
cells/well were seeded into 6-well plates, incubated 
overnight and then treated with simvastatin at different 
doses for 24 h. The cells were then collected, washed 
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with PBS and resuspended in 100 ul binding buffer. 
Subsequently, 1 ul of annexin V-FITC (100 ug/ml) and 
0.5 ul of propidium iodide (2 mg/ml) were added in the 
binding buffer and placed in the dark for 15 minutes. 
The samples were immediately measured by Cellometer. 
The results were analyzed by FCS4 express software 
(Molecular Devices, Sunnyvale, CA). All experiments 
were performed in triplicate to assess for consistency of 
response.
Cell cycle assay
The effects of simvastatin on cell cycle progression 
were measured by Cellometer. Briefly, 2.5 × 105 cells/well 
were seeded into 6-well plates, incubated overnight and 
then treated with simvastatin at different concentrations for 
24 h. The cells were harvested and washed with phosphate 
buffered saline (PBS). The pellet was re-suspended and 
fixed in 90% pre-chilled methanol and stocked overnight 
at −20°C. The cells were then washed with PBS again 
and resuspended in 50 μl RNase solution (250 ug/ml) 
and 10 mM EDTA for 30 minutes. Finally, 50 μl staining 
solution [containing 2 mg/ml PI (Biotium, Hayward, 
MA), 0.1 mg/ml Azide (Sigma-Aldrich), and 0.05% 
Triton X-100 (Sigma-Aldrich)] was added, and the final 
mixture was incubated for 15 minutes in the dark before 
being analyzed on Cellometer. The measured results were 
analyzed using the FCS4 express software (Molecular 
Devices, Sunnyvale, CA). Cell cycle analysis assay was 
performed in duplicate.
Adhesion assay
Each well in a 96-well plate was coated with 100 ul 
laminin-1 (10 ug/ml) and incubated at 37°C for 1 h. The 
fluid was then aspirated and 200 ul blocking buffer was 
added to each well for 45–60 min at 37°C. The wells were 
then washed with PBS, and the plate was allowed to chill 
on ice. To each well, 2.5 × 103 cells were added with PBS 
and varying concentrations of simvastatin directly. The 
plate was then allowed to incubate at 37°C for 2 h. After 
this period, the medium was aspirated, and the cells were 
fixed by directly adding 100 ul of 5% glutaraldehyde and 
incubating for 30 min at room temperature. Adhered cells 
were then washed with PBS and stained with 100 ul of 
0.1% crystal violet for 30 min. The cells were then washed 
repeatedly with water, and 100 ul of 10% acetic acid was 
added to each well to solubilize the dye. After 5 minutes 
of shaking, the absorbance was measured at 570 nm using 
a microplate reader from Tecan (Mannedorf, Switzerland). 
All experiments were performed in duplicate to assess for 
consistency of response.
Invasion assay
Cell invasion assays were performed using 96-well 
HTS transwells (Corning Life Sciences, Wilmington, NC) 
coated with 1X BME (Trevigen, Gaithersburg, Maryland). 
Starved (serum-free media for 12 h) Hey and SKOV3 
cells (50,000 cells/well) were seeded for 12 h in the 
upper chambers of the wells in 50 μl FBS-free medium, 
and the lower chambers were filled with 150 μl regular 
medium with simvastatin. The plate was incubated for 
24 h at 37°C to allow invasion into the lower chamber. 
After washing the upper and lower chambers with PBS 
once, 100 ul Calcein AM solution was added into the 
lower 37°C chamber and incubated for 30–60 min. The 
lower chamber plate was measured by the plate reader 
for reading fluorescence at EX/EM 485/520 nM. All 
experiments were performed in duplicate to assess for 
consistency of response.
Reactive oxygen species (ROS) assay
ROS generation was assessed using the ROS-
sensitive fluorescence indicator, DCFH-DA. To determine 
intracellular ROS scavenging activity, Hey and SKOV3 
cells (1.0 × 104 cells/well) were seeded in black 96-well 
plates. After 24 h, the cells were treated with simvastatin 
for 18 h to induce ROS generation. After the cells were 
incubated with DCFH-DA (20 μM) for 30 minutes, the 
fluorescence intensity was measured at an excitation 
wavelength of 485 nm and an emission wavelength 
of 530 nm using a fluorescence microplate reader. All 
experiments were performed in duplicate to assess for 
consistency of response.
DNA damage assay
High-molecular-weight DNA was isolated using 
a QIAamp DNA mini kit (QIAGEN, Venlo, Limberg) 
following the recommended protocol. The concentration 
of total cellular DNA was determined by using the 
Nanodrop (Tecan, Mannedorf, Switzerland). Quantitative 
PCR (qPCR) assays were performed as previously 
described with minor modifications [18, 21]. The primers 
for large fragments of the mtDNA (8.9 kb) are forward 
5′ - TCA AAG CCT CCT TAT TCG AGC CGA -3′, 
reverse 5′ – TTT CATCAT GCG GAG ATG TTG GAT 
GG - 3′, and primers for small mtDNA (221 bp) fragment 
are forward 5′ – CCC CAC AAA CCC CAT TAC TAA 
ACC CA -3′, reverse 5′ – TTT CATCAT GCG GAG ATG 
TTG GAT GG - 3′. A total volume of 50 μl was used in 
PCRs containing: 15 ng of template DNA, 5 pmol of each 
primer, 10X mix buffer and 2.5 units of recombinant Taq 
DNA polymerase High Fidelity (Invitrogen, Carlsbad, 
CA). A quantitative control using half the concentration 
of control template DNA was included in each set of 
PCR reactions. Small fragments (211 bp) of the mtDNA 
were also amplified for internal controls, respectively. 
The internal controls were used to normalize the results 
obtained from the large fragments and to monitor 
the mitochondrial copy number. The thermal cycling 
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conditions were as follows: 95°C for 3 min, followed by 
19 cycles of 94°C for 1 min, 64°C for 1 min and 68°C for 
9 min, primer extension at 72°C for 3 min at the end of 
these cycles. Every sample was tested in triplicate. qPCR 
products were quantitated using the Quant-iT™ dsDNA 
High Sensitivity Assay Kit. The average lesion frequency 
per each fragment was calculated by using the Poisson 
equation [19]. This experiment was done in duplicate to 
assess for consistency of response.
VEGF assay
VEGF levels of media, serum and ovarian cancer 
tissue homogenates were measured by the enzyme-linked 
immunoassay method using commercially available kits 
(human or mouse VEGF ELISA kit, RayBiotech, Inc., 
Norcross, GA,). The assay was conducted in triplicate.
Blood cholesterol
Blood cholesterol from the mice was measured by 
an automated blood chemical analyzer (Ortho Clinical 
Diagnostic Inc, Rochester, NY) in the UNC-CH Animal 
Facility Laboratory, Department of Pathology, UNC, 
Chapel Hill.
Western immunoblotting
Hey and SKOV3 cells were plated at 2–4 × 105 cells/
well in 6 well plates in their appropriate media and were 
treated with simvastatin for 24 h in 0.5% stripped serum. 
Cell lysates were prepared in RIPA buffer (1% NP40, 0.5 
sodium deoxycholate and 0.1% SDS) plus PhosStop. Equal 
amounts of protein were separated by gel electrophoresis 
and transferred onto a PVDF membrane. The membrane 
was blocked with 5% nonfat dry milk and then incubated 
with a 1:1000 dilution of primary antibody overnight at 
4°C. The membrane was then washed and incubated with 
a secondary peroxidase conjugated antibody for 1 hour 
after washing. Antibody binding was detected using an 
enhanced chemiluminescence detection buffer and the 
Alpha Innotech imaging system (San Leandro, CA). After 
developing, the membrane was re-probed using antibody 
against α-tubulin or β-actin. Each experiment was repeated 
three times to assess for consistency of results.
Ovarian cancer tissue sample collection and 
primary cell culture
Seven tumor specimens were sampled from patients 
undergoing surgery for ovarian cancer at the University of 
North Carolina at Chapel Hill. The protocol was reviewed 
and exemption granted by the Institutional Review Board 
at the University. Freshly obtained tissues were washed 
three times with Hank’s Buffered Salt Solution (HBSS), 
and then gently minced by scissors in DMEM/F12 medium 
containing 10% fetal bovine serum (FBS). Primary cultures 
were performed as described [23]. 2 × 104 primary culture 
cells/well were seeded into 96-well plates and incubated for 
24 h before treatment with simvastatin. Cell proliferation 
was measured by MTT assay 72 h after treatment.
Orthotropic xenografts of serous ovarian cancer
The K18-gT121+/- p53fl/fl Brca1fl/fl (KpB) mouse 
model is a unique serous ovarian cancer mouse model that 
specifically and somatically deletes the tumor suppressor 
genes, Brca1 and p53, and inactivates the retinoblastoma 
(Rb) proteins in adult ovarian surface epithelial cells (KpB 
mouse model) [22]. As an extension of this model, we 
have established an ovarian tumor cell line from one of the 
KpB mice (M909). Upon re-injection of these tumor cells 
into the ovarian bursa of female mice, we have developed 
a more aggressive variant of the KpB model [23]. For 
the evaluation of simvastatin’s in vivo effects, M909 
cells (1 × 106 cells/5 μl) were injected into the left side 
of the ovarian bursa of 6–8 week old mice. All mice were 
handled according to protocols approved by UNC-CH 
Institutional Animal Care and Use Committee (IACUC). 
Twenty two mice were injected with the M909 cells and 
then randomly divided into the control and simvastatin 
groups. The simvastatin treatment (intraperitoneal 
injection, 3 mg/kg/day) was initiated twelve days after the 
injection, and tumor size was checked twice a week using 
palpation until tumors had grown to a size amenable to 
caliper measurement. Tumor volume was calculated using 
the following equation (width2 × length)/2. All mice were 
euthanized after four weeks of simvastatin or placebo 
treatment. Tumor tissue and blood samples were collected 
for immunohistochemical staining and VEGF assay.
Immunohistochemistry
Five micrometer paraffin sections prepared from 
the transgenic mice were used for immunohistochemical 
analysis. Staining procedures were performed at 
Histology Research Core Facility at UNC. The following 
primary antibodies were used: Ki-67, HMGCR, cleaved 
caspase 3, phos-AKT and phos-p42/44 expression. 
Further processing was carried out using ABC-Staining 
Kits (Vector Labs, Burlingame, CA) and hematoxylin. 
Immunochemistry slides were scanned, analyzed and 
scored by Aperio and ImageScope software (Vista, CA).
Statistical analysis
Results were compared by Student’s t test and data 
were expressed as mean ± S.E. Statistical significance was 
defined to be p < 0.05.
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